Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis
Ruben Mujica-Mota*, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage, Martin Hoyle
*Corresponding author for this work
Research output: Contribution to journal › Review article (Academic Journal) › peer-review
24
Citations
(Scopus)